A Randomised, Double-blind, Placebo-controlled, Parallel-group Exploratory Trial to Investigate the Effect of FE 999302 When Administered During Different Time Intervals in Women Undergoing Controlled Ovarian Stimulation With a Fixed Dose of Follitropin Delta in a Gonadotropin-releasing Hormone Antagonist Protocol
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Chorionic gonadotropin (Primary) ; Follitropin delta (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Acronyms Celestial-2
- Sponsors Ferring Pharmaceuticals
Most Recent Events
- 24 Jan 2025 Planned End Date changed from 4 May 2026 to 13 Jul 2026.
- 26 Jul 2024 New trial record